TL;DR
A novel PIK3R1-CCDC178 gene fusion in ovarian cancer drives chemoresistance and increased cell migration not by activating the expected PI3K-AKT-mTOR pathway, but by activating ERK1/2. This fusion also leads to the formation of unique rod and ring-like cellular structures containing CIN85, which appear to be a key mechanism for platinum resistance.
What Problem Does This Paper Address?
High-grade serous ovarian cancer (HGSC) is a deadly disease with limited treatment options, often exacerbated by acquired resistance to chemotherapy. Gene fusions are common in HGSC, suggesting they play a role in tumorigenesis and drug resistance, but their specific pathogenic mechanisms remain poorly understood. This paper investigates the functional role of a specific PIK3R1-CCDC178 gene fusion found in HGSC, aiming to elucidate how it contributes to cancer progression and treatment resistance.
Methods
The researchers employed a multi-faceted approach:
- Cell Culture and Transfection: They used OVCAR-8 (HGSC) and HEK293 cells, stably transfecting them with either a control vector or the PIK3R1-CCDC178 fusion construct.
- Functional Assays:
- Colony Formation Assay: To assess cell survival under various drug treatments.
- Cell Viability Assay (MTS): To measure cell death in response to chemotherapy.
- Cell Migration Assay (Wound Healing): To quantify the ability of cells to migrate and invade.
- Molecular Analysis:
- Western Blotting: To analyze protein expression and phosphorylation levels of key signaling pathway components (PI3K-AKT-mTOR, ERK1/2).
- Immunoprecipitation (IP) followed by LC-ESI-MS/MS: To identify proteins that interact with the PIK3R1 fusion protein within cellular structures.
- Immunofluorescence Staining: To visualize the localization of the fusion protein and other cellular components.
- Correlative Light-Electron Microscopy (CLEM): To provide high-resolution structural information about the protein complexes.
- In Situ Hybridization: To confirm the presence of the fusion transcript.
Datasets
Not explicitly detailed as distinct datasets for training/evaluation in the context of machine learning. The study utilizes patient-derived HGSC samples for initial fusion identification and then relies on established cell lines (OVCAR-8, HEK293) for experimental validation.
Key Insights and Ideas
- Unexpected Pathway Activation: The most striking finding is that the PIK3R1 fusion doesn't activate the PI3K-AKT-mTOR pathway as initially hypothesized, despite PIK3R1 being a known regulator of this pathway. Instead, it paradoxically activates the ERK1/2 pathway. This highlights the complexity of fusion protein function and the need to look beyond direct pathway interactions.
- CIN85 as a Key Player: The adaptor protein CIN85 emerges as a crucial component. Its expression is upregulated in fusion-expressing cells, and it colocalizes with the PIK3R1 fusion protein in unique cellular structures. CIN85 is known to interact with PIK3R1 and also plays a role in the ERK pathway, bridging the fusion protein to its observed effects.
- Rod and Ring-like Structures (RRs) as a Resistance Mechanism: The formation of these novel rod and ring-like structures, containing both the fusion protein and CIN85, is directly linked to platinum resistance. This suggests a previously unrecognized mechanism of cell survival and drug resistance.
- ERK1/2 Activation is Central: The study strongly links ERK1/2 activation to both increased cell migration and chemoresistance, mediated by the PIK3R1 fusion. Inhibition of ERK1/2 partially rescues the migratory phenotype, underscoring its importance.
- Fusion Protein Structure and Function: The fusion protein is a truncated p85α with an altered CCDC178 C-terminus, lacking key domains for PI3K regulation but retaining an SH3 domain that can interact with CIN85. This structural alteration is key to its novel function.
Key Results
- Increased Migration: PIK3R1 fusion-expressing cells exhibited significantly enhanced motility compared to control cells.
- Chemoresistance: Cells with the PIK3R1 fusion showed increased resistance to cisplatin and trametinib.
- ERK1/2 Activation: Western blot analysis revealed elevated phosphorylation of ERK1/2 in fusion-expressing cells, which was partially reversed by a Ras inhibitor but remained elevated even with a MEK inhibitor.
- RR Formation: Cisplatin and trametinib treatment induced the formation of rod and ring-like structures in fusion-expressing cells, and the presence and size of these structures correlated with treatment resistance.
- CIN85 Colocalization: The PIK3R1 fusion protein was found to colocalize with CIN85 within these RR-like structures, particularly after cisplatin treatment.
- Protein Composition of RRs: Mass spectrometry identified CIN85 and several stress/folding-related proteins, along with the fusion protein itself, as major components of these structures.
Limitations and Future Work
- Mechanism of RR Formation: While the study identifies CIN85 and the fusion protein in RRs and links them to resistance, the precise molecular mechanisms by which these structures confer resistance to platinum and trametinib require further investigation.
- Generalizability of RR Mechanism: The authors suggest that RR formation might be a more general cell survival mechanism in drug resistance, but this needs to be explored in other contexts.
- PI3K-AKT-mTOR Pathway: Although the study found the PI3K-AKT-mTOR pathway to be largely unaffected downstream, the observed decrease in native p85α phosphorylation warrants further investigation into how the fusion might indirectly influence this pathway.
- Clinical Relevance: While the fusion was identified in a patient, further studies are needed to determine its prevalence in a larger HGSC cohort and its direct impact on patient outcomes.
- Targeting the Fusion: The study suggests that targeting ERK1/2 is a more promising therapeutic strategy than targeting the PI3K pathway directly for cancers harboring this fusion. Future work could explore the efficacy of combined therapies targeting ERK1/2 and potentially other components of the RR structures.
Summary updated